Cargando…
Formulation Development of Mirtazapine Liquisolid Compacts: Optimization Using Central Composite Design
Mirtazapine is a tetracyclic anti-depressant with poor water solubility. The aim of this study was to improve the dissolution rate of mirtazapine by delivering the drug as a liquisolid compact. Central composite design (CCD) was employed for the preparation of mirtazapine liquisolid compacts. In thi...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9268088/ https://www.ncbi.nlm.nih.gov/pubmed/35807252 http://dx.doi.org/10.3390/molecules27134005 |
_version_ | 1784743894251995136 |
---|---|
author | Naureen, Faiza Shah, Yasar Shah, Sayyed Ibrahim Abbas, Muhammad Rehman, Inayat Ur Muhammad, Salar , Hamdullah Goh, Khang Wen Khuda, Fazli Khan, Amjad Chan, Siok Yee Mushtaq, Mehwish Ming, Long Chiau |
author_facet | Naureen, Faiza Shah, Yasar Shah, Sayyed Ibrahim Abbas, Muhammad Rehman, Inayat Ur Muhammad, Salar , Hamdullah Goh, Khang Wen Khuda, Fazli Khan, Amjad Chan, Siok Yee Mushtaq, Mehwish Ming, Long Chiau |
author_sort | Naureen, Faiza |
collection | PubMed |
description | Mirtazapine is a tetracyclic anti-depressant with poor water solubility. The aim of this study was to improve the dissolution rate of mirtazapine by delivering the drug as a liquisolid compact. Central composite design (CCD) was employed for the preparation of mirtazapine liquisolid compacts. In this, the impacts of two independent factors, i.e., excipient ratio (carrier:coating) and different drug concentration on the response of liquisolid system were optimized. Liquisolid compacts were prepared using propylene glycol as a solvent, microcrystalline cellulose as a carrier, and silicon dioxide (Aerosil) as the coating material. The crystallinity of the formulated drug and the interactions between the excipients were examined using X-ray powder diffraction (XRD) and Fourier-transform infrared spectroscopy (FTIR), respectively. The dissolution study for the liquisolid compact was carried out as per FDA guidelines. The results showed loss of crystallinity of the mirtazapine in the formulation and was completely solubilized in non-volatile solvent and equally dispersed throughout the powder system. Moreover, drug dissolution was found to be higher in liquisolid compacts than the direct compressed conventional tablets (of mirtazapine). The liquisolid technique appears to be a promising approach for improving the dissolution of poorly soluble drugs like mirtazapine. |
format | Online Article Text |
id | pubmed-9268088 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-92680882022-07-09 Formulation Development of Mirtazapine Liquisolid Compacts: Optimization Using Central Composite Design Naureen, Faiza Shah, Yasar Shah, Sayyed Ibrahim Abbas, Muhammad Rehman, Inayat Ur Muhammad, Salar , Hamdullah Goh, Khang Wen Khuda, Fazli Khan, Amjad Chan, Siok Yee Mushtaq, Mehwish Ming, Long Chiau Molecules Article Mirtazapine is a tetracyclic anti-depressant with poor water solubility. The aim of this study was to improve the dissolution rate of mirtazapine by delivering the drug as a liquisolid compact. Central composite design (CCD) was employed for the preparation of mirtazapine liquisolid compacts. In this, the impacts of two independent factors, i.e., excipient ratio (carrier:coating) and different drug concentration on the response of liquisolid system were optimized. Liquisolid compacts were prepared using propylene glycol as a solvent, microcrystalline cellulose as a carrier, and silicon dioxide (Aerosil) as the coating material. The crystallinity of the formulated drug and the interactions between the excipients were examined using X-ray powder diffraction (XRD) and Fourier-transform infrared spectroscopy (FTIR), respectively. The dissolution study for the liquisolid compact was carried out as per FDA guidelines. The results showed loss of crystallinity of the mirtazapine in the formulation and was completely solubilized in non-volatile solvent and equally dispersed throughout the powder system. Moreover, drug dissolution was found to be higher in liquisolid compacts than the direct compressed conventional tablets (of mirtazapine). The liquisolid technique appears to be a promising approach for improving the dissolution of poorly soluble drugs like mirtazapine. MDPI 2022-06-22 /pmc/articles/PMC9268088/ /pubmed/35807252 http://dx.doi.org/10.3390/molecules27134005 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Naureen, Faiza Shah, Yasar Shah, Sayyed Ibrahim Abbas, Muhammad Rehman, Inayat Ur Muhammad, Salar , Hamdullah Goh, Khang Wen Khuda, Fazli Khan, Amjad Chan, Siok Yee Mushtaq, Mehwish Ming, Long Chiau Formulation Development of Mirtazapine Liquisolid Compacts: Optimization Using Central Composite Design |
title | Formulation Development of Mirtazapine Liquisolid Compacts: Optimization Using Central Composite Design |
title_full | Formulation Development of Mirtazapine Liquisolid Compacts: Optimization Using Central Composite Design |
title_fullStr | Formulation Development of Mirtazapine Liquisolid Compacts: Optimization Using Central Composite Design |
title_full_unstemmed | Formulation Development of Mirtazapine Liquisolid Compacts: Optimization Using Central Composite Design |
title_short | Formulation Development of Mirtazapine Liquisolid Compacts: Optimization Using Central Composite Design |
title_sort | formulation development of mirtazapine liquisolid compacts: optimization using central composite design |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9268088/ https://www.ncbi.nlm.nih.gov/pubmed/35807252 http://dx.doi.org/10.3390/molecules27134005 |
work_keys_str_mv | AT naureenfaiza formulationdevelopmentofmirtazapineliquisolidcompactsoptimizationusingcentralcompositedesign AT shahyasar formulationdevelopmentofmirtazapineliquisolidcompactsoptimizationusingcentralcompositedesign AT shahsayyedibrahim formulationdevelopmentofmirtazapineliquisolidcompactsoptimizationusingcentralcompositedesign AT abbasmuhammad formulationdevelopmentofmirtazapineliquisolidcompactsoptimizationusingcentralcompositedesign AT rehmaninayatur formulationdevelopmentofmirtazapineliquisolidcompactsoptimizationusingcentralcompositedesign AT muhammadsalar formulationdevelopmentofmirtazapineliquisolidcompactsoptimizationusingcentralcompositedesign AT hamdullah formulationdevelopmentofmirtazapineliquisolidcompactsoptimizationusingcentralcompositedesign AT gohkhangwen formulationdevelopmentofmirtazapineliquisolidcompactsoptimizationusingcentralcompositedesign AT khudafazli formulationdevelopmentofmirtazapineliquisolidcompactsoptimizationusingcentralcompositedesign AT khanamjad formulationdevelopmentofmirtazapineliquisolidcompactsoptimizationusingcentralcompositedesign AT chansiokyee formulationdevelopmentofmirtazapineliquisolidcompactsoptimizationusingcentralcompositedesign AT mushtaqmehwish formulationdevelopmentofmirtazapineliquisolidcompactsoptimizationusingcentralcompositedesign AT minglongchiau formulationdevelopmentofmirtazapineliquisolidcompactsoptimizationusingcentralcompositedesign |